PCT-52: VIMANG®: Mangifera indica L. EXTRACT AS DERMATOLOGICAL PROTECTOR DURING RADIATION TREATMENT

J Pharm Pharmacogn Res 3(suppl. 1): S144, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Poster

PCT-52: VIMANG®: Mangifera indica L. EXTRACT AS DERMATOLOGICAL PROTECTOR DURING RADIATION TREATMENT

Gil D, Fleitas R, Cruz JL.

Hospital Docente Clínico Quirúrgico “Dr. Salvador Allende”. Calzada del Cerro, No.1551 esq. Domínguez, Municipio Cerro, La Habana, Cuba. CP: 12000. E-mail: dorisgil@infomed.sld.cu

 

Introduction: The radiodermitis is an illness of the skin that affects the patients that have maintained exposed any area of the body to the action of the radiations ionizantes emitted by the equipment of radio diagnosis or therapeutic treatments. It is classified as acute or chronicle diseases. The incidence during the treatment with radiations of the wicked tumors varies among the 20 – 80%. Material and Methods: A total of 83 patients were studied in relationship to effectiveness and security of the Vimang® cream like part of open, randomized clinical trial phase II. During the treatment with radiotherapy, the patients were divided in two groups, one with 41 cases, tried with the cream Vimang® and another with 43 individuals that used the local hygienic measures, according to the established protocols. In the studied sample, the 60-69 year-old ages prevailed (36.14%), the masculine sex (57.83%) and the white race with 50 cases (60.24%). The radiation dose more frequently received was 200 cGy, as daily total dose (DTD) and 50 Gy, as total dose of the tumor (DTT). Results: One case presented radiodermitis in the group tried with the Vimang® cream, while they happened seven cases in the control group. One patient belonging to the group tried with the cream was reported as radiodermitis degree I, without necessity of suspending the radiant treatment and the lesions disappeared with the continuous use of the cream. All the patients of the group control, showed radiodermitis degree II and the radiotherapy were suspended in a case. An individual tried with Vimang®, presented as adverse event, pruritus degree I in the first week, and it disappeared with the time, without necessity of suspending the treatment. Conclusions: The Vimang® cream diminished the radiodermitis appearance, what suggests the possibilities of its use as dermatologic protective drug.

 

Citation Format: Gil D, Fleitas R, Cruz JL (2015) Vimang®: Mangifera indica L. extract as dermatological protector during radiation treatment. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S144. Abstract nr PCT-52.